A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO).

Sehouli, J., Tomè, O., Dimitrova, D., Camara, O., Runnebaum, I.B., Tessen, H.W., Rautenberg, B., Chekerov, R., Muallem, M.Z., Lux, M.P., Trarbach, T., Gitsch, G., 2016.

J. Cancer Res. Clin. Oncol. 143(3), 541–550. doi:10.1007/s00432-016-2307-0

Studie: Treosulfan-Studie; Indikation: Sonstige; Jahr: 2016; Veranstaltung: -; Journal: Journal of Cancer Research and Clinical Oncology

Ellen-Gottlieb-Straße 19
79106 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com